Cargando…

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Background: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson’s disease dementia or dementia with Lewy bodies. Objectives: The primary outcomes of this study were safety and tolerability; pharmacokinetics and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagan, Fernando, Hebron, Michaeline, Valadez, Ellen H., Torres-Yaghi, Yasar, Huang, Xu, Mills, Reversa R., Wilmarth, Barbara M., Howard, Hellen, Dunn, Connell, Carlson, Alexis, Lawler, Abigail, Rogers, Sean L., Falconer, Ramsey A., Ahn, Jaeil, Li, Zhaoxia, Moussa, Charbel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2016
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008228/ https://www.ncbi.nlm.nih.gov/pubmed/27434297 http://dx.doi.org/10.3233/JPD-160867

Ejemplares similares

Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease
por: Pagan, Fernando L., et al.
Publicado: (2020)

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies
por: Pagan, Fernando L., et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease
por: Pagan, Fernando L., et al.
Publicado: (2019)

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial
por: Pagan, Fernando. L., et al.
Publicado: (2020)

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
por: Turner, Raymond S., et al.
Publicado: (2020)

4564 Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the cerebrospinal fluid of Parkinson’s patients
por: Fowler, Alan, et al.
Publicado: (2020)

CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
por: Fowler, Alan J., et al.
Publicado: (2021)

Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients
por: Anderson, Karen E., et al.
Publicado: (2022)

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease
por: Stevenson, Max, et al.
Publicado: (2023)

Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration
por: Hebron, Michaeline, et al.
Publicado: (2015)

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
por: Moussa, Charbel, et al.
Publicado: (2017)

Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy
por: Hebron, Michaeline L., et al.
Publicado: (2014)

Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models
por: Lonskaya, Irina, et al.
Publicado: (2014)

Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
por: Lonskaya, Irina, et al.
Publicado: (2013)

Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology
por: Liu, Xiaoguang, et al.
Publicado: (2021)

Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance
por: Lonskaya, Irina, et al.
Publicado: (2013)

Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A
por: Mills, Reversa R, et al.
Publicado: (2015)

Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases
por: Desforges, Nicole M., et al.
Publicado: (2012)

Inhibition of Ubiquitin-Specific Protease-13 Improves Behavioral Performance in Alpha-Synuclein Expressing Mice
por: Liu, Xiaoguang, et al.
Publicado: (2022)

Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
por: Fowler, Alan J., et al.
Publicado: (2019)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Nilotinib based pharmacophore models for BCRABL
por: Sabitha, Kesavan
Publicado: (2012)

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Effects of nilotinib on regulatory T cells: the dose matters
por: Fei, Fei, et al.
Publicado: (2010)

Nilotinib-induced Perforating Folliculitis: Two Cases
por: Saraswat, Neerja, et al.
Publicado: (2018)

Nilotinib: QTc prolongation: 2 case reports
Publicado: (2021)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Sialorrhea in Parkinson’s Disease
por: Isaacson, Jonathan, et al.
Publicado: (2020)

Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings
por: Peterson, Bethany, et al.
Publicado: (2019)

60941 Vaginal pH predicts cervical intraepithelial neoplasia-2 regression in women living with human immunodeficiency virus
por: Michel, Katherine, et al.
Publicado: (2021)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Hepatitis B Virus Reactivation under Treatment with Nilotinib
por: Temel, Tuncer, et al.
Publicado: (2015)

Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
por: Contreras, Osvaldo, et al.
Publicado: (2018)

A Case of Severe, Nilotinib-Induced Liver Injury
por: Belopolsky, Yuliya, et al.
Publicado: (2019)

Nilotinib-induced liver injury: A case report
por: Tan, Youwen, et al.
Publicado: (2020)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1dg9s8d4gu5q1kprp60c13h3vq